![PDF) Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial) PDF) Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial)](https://i1.rgstatic.net/publication/356748127_Avelumab_as_neoadjuvant_therapy_in_patients_with_urothelial_non-metastatic_muscle_invasive_bladder_cancer_a_multicenter_randomized_non-comparative_phase_II_study_Oncodistinct_004_-_AURA_trial/links/61a9a895aade5b1bf5fdc73f/largepreview.png)
PDF) Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial)
![Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program | Journal for ImmunoTherapy of Cancer Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program | Journal for ImmunoTherapy of Cancer](https://jitc.bmj.com/content/jitc/8/1/e000313/F1.large.jpg?download=true)
Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program | Journal for ImmunoTherapy of Cancer
![Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study - The Lancet Oncology Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/0ee290c6-dd2a-4652-aab5-0af7643c80ea/gr1.gif)
Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study - The Lancet Oncology
![European Commission Approves BAVENCIO® (avelumab) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma European Commission Approves BAVENCIO® (avelumab) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma](https://mma.prnewswire.com/media/1136289/EMD_Serono_Logo.jpg?p=twitter)
European Commission Approves BAVENCIO® (avelumab) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
![Avelumab Maintenance Therapy in Bladder Cancer | NEJM Resident 360 <meta property="twitter:image" content="https://resident360files.nejm.org/image/upload/c_fit,f_auto,h_120,w_120/v1538599218/u8buf4o8mgdxgmfcczjk.png" /> <meta property="og:image ... Avelumab Maintenance Therapy in Bladder Cancer | NEJM Resident 360 <meta property="twitter:image" content="https://resident360files.nejm.org/image/upload/c_fit,f_auto,h_120,w_120/v1538599218/u8buf4o8mgdxgmfcczjk.png" /> <meta property="og:image ...](https://files.medstro.com/image/authenticated/s--z-MEaetY--/NEJMoa2002788_f1.jpg)
Avelumab Maintenance Therapy in Bladder Cancer | NEJM Resident 360 <meta property="twitter:image" content="https://resident360files.nejm.org/image/upload/c_fit,f_auto,h_120,w_120/v1538599218/u8buf4o8mgdxgmfcczjk.png" /> <meta property="og:image ...
![Formatting and gene-based delivery of a human PD-L1 single domain antibody for immune checkpoint blockade: Molecular Therapy - Methods & Clinical Development Formatting and gene-based delivery of a human PD-L1 single domain antibody for immune checkpoint blockade: Molecular Therapy - Methods & Clinical Development](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/d91f1564-6868-44cf-9ccb-8dfdca18bc9c/gr5.jpg)
Formatting and gene-based delivery of a human PD-L1 single domain antibody for immune checkpoint blockade: Molecular Therapy - Methods & Clinical Development
![Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial - The Lancet Oncology Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2a06f959-4933-45e3-98f1-21f02e1c6b49/gr1_lrg.gif)